Related Experiment Video

Updated: Oct 30, 2025

Experimental Metastasis Assay
08:28

Experimental Metastasis Assay

Published on: August 24, 2010

20.5K

LRG1 Promotes Metastatic Dissemination of Melanoma through Regulating EGFR/STAT3 Signalling

Yuet Ping Kwan1,2, Melissa Hui Yen Teo1,2, Jonathan Chee Woei Lim3

  • 1Centre for Vision Research, Duke NUS Medical School, 8 College Road, Singapore 169857, Singapore.

Cancers
|July 2, 2021
PubMed

Insights

Leucine-rich α-2-glycoprotein 1 (LRG1) promotes melanoma metastasis but not tumor growth. Targeting LRG1 may offer a new strategy for treating metastatic melanoma, a deadly skin cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Melanoma is a deadly skin cancer with limited treatment options for metastatic disease.
  • Understanding melanoma's molecular mechanisms is crucial for developing targeted therapies.
  • Leucine-rich α-2-glycoprotein 1 (LRG1) is investigated for its role in melanoma.

Purpose of the Study:

  • To investigate the role of LRG1 in melanoma development and progression.
  • To determine if LRG1 influences melanoma cell growth, proliferation, angiogenesis, migration, invasion, and adhesion.
  • To elucidate the molecular pathways through which LRG1 affects melanoma metastasis.

Main Methods:

  • Analysis of LRG1 expression in human melanoma biopsies and mouse cell lines.
  • Comparison of tumor growth and metastasis in wild-type and LRG1-deficient mice.
  • In vitro assays to assess melanoma cell migration, invasion, and adhesion.
  • Investigation of EGFR/STAT3 signaling pathway involvement.

Main Results:

  • LRG1 expression is significantly induced in metastatic melanoma cells.
  • Absence of host LRG1 did not affect tumor cell growth, proliferation, or angiogenesis.
  • LRG1 deficiency significantly reduced melanoma cell metastasis to the lungs.
  • LRG1 promotes melanoma cell migration, invasion, and adhesion.
  • LRG1 mediates melanoma cell invasiveness via an EGFR/STAT3-dependent pathway.

Conclusions:

  • LRG1 is essential for melanoma metastasis but not for tumor growth.
  • Targeting LRG1 presents a potential therapeutic strategy for controlling malignant melanoma.
  • LRG1's role in promoting metastasis via EGFR/STAT3 signaling offers insights into melanoma pathophysiology.
Keywords:
EGFRSTAT3leucine-rich α-2-glycoprotein-1melanomametastasis

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.6K
A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.1K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.3K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.7K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.4K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K